Research Use Only Application: Antibody conjugation Reagent for Targeted cell death, Targeted cell death for cancer cells, High-throughput screening with cell killing assays oYo-Link DM1 is an Antibody-Drug Conjugation Reagent allowing for site-specific labeling of DM1 drug labels to the heavy-chains of compatible antibodies with up to two labels per antibody. oYo-Link limits the attachment of the DBCO drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 DBCO drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. As a synthetic derivative of the microtubule-targeted agent mertansine, also known as the maytansinoid DM1, the DM1 ADC is an antibody-conjugatable, anti-mitotic agent that overcomes systemic toxicity associated with mertansine and enhances tumor-specific delivery. The antibody labeling procedure simply requires mixing oYo-Link DM1 with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog AT7002 Requirements: To label your compatible antibodies with oYo-Link, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaTheras LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support alphathera.com
Konzentration:
337 µg/mL
Molekulargewicht:
10 kDa
Puffer:
PBS
Formulierung:
Dried pellet
oYo-Link DM1 Product Icon
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
